Aura Biosciences, Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, AURA reported earnings of -0.40 USD per share (EPS) for Q3 25, beating the estimate of -0.47 USD, resulting in a 15.93% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.72% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Aura Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Aura Biosciences, Inc. Common Stock reported EPS of -$0.40, beating estimates by 15.93%, and revenue of $0.00, 0% as expectations.
How did the market react to Aura Biosciences, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -0.72%, changed from $5.57 before the earnings release to $5.53 the day after.
When is Aura Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Aura Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Aura Biosciences, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.